---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-016108"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:09:42.444349+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tonix reports preliminary Q3 net loss $32M, plans Tonmya launch by Nov 2025

## Summary
- Preliminary Q3 2025 net loss ~$32.0M vs $14.2M YoY; net revenue $3.3M vs $2.8M.
- Cash and equivalents ~$190.1M at Sept 30, 2025; net operating cash use $28.8M.
- Subsequent equity offerings net $29.3M; cash runway into Q1 2027.
- U.S. commercial launch of Tonmya for fibromyalgia expected by end of Nov 2025.

## SEC filing metadata
- accession: 0001999371-25-016108
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/0001999371-25-016108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/tnxp_8k-102725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-016108
- JSON: https://secwatch.observer/filing/0001999371-25-016108.json
- Plain text: https://secwatch.observer/filing/0001999371-25-016108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.